Non-Albumin Proteinuria (NAP) As a Complementary Marker for Diabetic Kidney Disease (DKD)

Overview

Journal Life (Basel)

Specialty Biology

Date 2021 Apr 3

PMID 33802211

Citations 2

Authors

Jaehyun Bae

Young Jun Won

Byung-Wan Lee

Affiliations

Soon will be listed here.

Abstract

Diabetic kidney disease (DKD) is one of the most common forms of chronic kidney disease. Its pathogenic mechanism is complex, and it can affect entire structures of the kidney. However, conventional approaches to early stage DKD have focused on changes to the glomerulus. Current standard screening tools for DKD, albuminuria, and estimated glomerular filtration rate are insufficient to reflect early tubular injury. Therefore, many tubular biomarkers have been suggested. Non-albumin proteinuria (NAP) contains a wide range of tubular biomarkers and is convenient to measure. We reviewed the clinical meanings of NAP and its significance as a marker for early stage DKD.

Citing Articles

Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease.

Bae J, Lee B Biomedicines. 2023; 11(7).

PMID: 37509567 PMC: 10377561. DOI: 10.3390/biomedicines11071928.

Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria.

DMarco L, Guerra-Torres X, Viejo I, Lopez-Romero L, Yugueros A, Bermidez V touchREV Endocrinol. 2023; 18(2):102-105.

PMID: 36694889 PMC: 9835813. DOI: 10.17925/EE.2022.18.2.102.

References

Halimi J, Matthias B, Al-Najjar A, Laouad I, Chatelet V, Marliere J . Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients. Am J Transplant. 2007; 7(12):2775-81. DOI: 10.1111/j.1600-6143.2007.02010.x. View

Lindenmeyer M, Kretzler M, Boucherot A, Berra S, Yasuda Y, Henger A . Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol. 2007; 18(6):1765-76. DOI: 10.1681/ASN.2006121304. View

Molitch M, Steffes M, Sun W, Rutledge B, Cleary P, de Boer I . Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care. 2010; 33(7):1536-43. PMC: 2890355. DOI: 10.2337/dc09-1098. View

Hong N, Lee M, Park S, Lee Y, Jin S, Kim J . Elevated urinary N-acetyl-β-D-glucosaminidase is associated with high glycoalbumin-to-hemoglobin A1c ratio in type 1 diabetes patients with early diabetic kidney disease. Sci Rep. 2018; 8(1):6710. PMC: 5928247. DOI: 10.1038/s41598-018-25023-5. View

Parving H . Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens Suppl. 1996; 14(2):S89-93; discussion S93-4. DOI: 10.1097/00004872-199609002-00017. View

Mogensen C . Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia. 1999; 42(3):263-85. DOI: 10.1007/s001250051151. View

Katayev A, Zebelman A, Sharp T, Flynn S, Bernstein R . Prevalence of isolated non-albumin proteinuria in the US population tested for both, urine total protein and urine albumin: An unexpected discovery. Clin Biochem. 2016; 50(6):262-269. DOI: 10.1016/j.clinbiochem.2016.11.030. View

Sakatsume M, Kubota R, Ogawa A, Narita I, Matsuda T, Shiba K . Rapid and sensitive electrophoresis of urinary protein clearly reveals the pathophysiological feature of renal diseases. Nephrology (Carlton). 2007; 12(2):191-6. DOI: 10.1111/j.1440-1797.2006.00739.x. View

Kramer H, Nguyen Q, Curhan G, Hsu C . Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003; 289(24):3273-7. DOI: 10.1001/jama.289.24.3273. View

10.

Dekkers C, Petrykiv S, Laverman G, Cherney D, Gansevoort R, Heerspink H . Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018; 20(8):1988-1993. PMC: 6055757. DOI: 10.1111/dom.13301. View

11.

. 11. Microvascular Complications and Foot Care: . Diabetes Care. 2020; 44(Suppl 1):S151-S167. DOI: 10.2337/dc21-S011. View

12.

Thomas M, MacIsaac R, Jerums G, Weekes A, Moran J, Shaw J . Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care. 2009; 32(8):1497-502. PMC: 2713618. DOI: 10.2337/dc08-2186. View

13.

Mohammadi-Karakani A, Asgharzadeh-Haghighi S, Ghazi-Khansari M, Hosseini R . Determination of urinary enzymes as a marker of early renal damage in diabetic patients. J Clin Lab Anal. 2007; 21(6):413-7. PMC: 6649252. DOI: 10.1002/jcla.20212. View

14.

Hong C, Hughes K, Chia K, Ng V, Ling S . Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care. 2003; 26(2):338-42. DOI: 10.2337/diacare.26.2.338. View

15.

Bonventre J . Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant. 2009; 24(11):3265-8. DOI: 10.1093/ndt/gfp010. View

16.

Korner A, Eklof A, Celsi G, Aperia A . Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes. 1994; 43(5):629-33. DOI: 10.2337/diab.43.5.629. View

17.

Krolewski A . Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2015; 38(6):954-62. PMC: 4439536. DOI: 10.2337/dc15-0184. View

18.

Kim J, Kim S, Kim I, Lee M, Jeon Y, Kim B . Nonalbumin proteinuria is a simple and practical predictor of the progression of early-stage type 2 diabetic nephropathy. J Diabetes Complications. 2016; 31(2):395-399. DOI: 10.1016/j.jdiacomp.2016.11.009. View

19.

Al-Hazmi S, Gad H, Alamoudi A, Eldakhakhny B, Binmahfooz S, Alhozali A . Evaluation of early biomarkers of renal dysfunction in diabetic patients. Saudi Med J. 2020; 41(7):690-697. PMC: 7502923. DOI: 10.15537/smj.2020.7.25168. View

20.

Kim S, Song S, Kim I, Yang J, Lee J, Kwak I . Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. Diabetes Res Clin Pract. 2012; 97(2):251-7. DOI: 10.1016/j.diabres.2012.02.019. View